Published in Food and Drug Law Weekly, May 30th, 2008
"Our first quarter announcement that the toremifene 80 mg Phase III ADT clinical trial met its primary endpoint was a transformational event for GTx," said Mitchell S. Steiner, M.D., CEO of GTx. "We plan to file the New Drug Application with FDA this summer and are preparing for a launch of toremifene 80 mg in 2009. We have initiated the process for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.